

# Michael E Nassif

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2985299/michael-e-nassif-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

6

papers

231

citations

5

h-index

6

g-index

6

ext. papers

322

ext. citations

10.2

avg, IF

3.25

L-index

#	Paper	IF	Citations
6	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1426-1430	6.7	5
5	Influence of Donor Transmitted and Rapidly Progressive Coronary Vascular Disease on Long-Term Outcomes After Heart Transplantation: A Contemporary Intravascular Ultrasound Analysis. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 464-472	3.3	2
4	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. <i>Circulation</i> , <b>2019</b> , 140, 1463-1476	16.7	163
3	Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21 Suppl 2, 19-23	6.7	16
2	Effect of glucose-lowering therapies on heart failure. <i>Nature Reviews Cardiology</i> , <b>2018</b> , 15, 282-291	14.8	34
1	Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes. <i>Circulation</i> , <b>2018</b> , 138, 4-6	16.7	11